BioVie Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIVI research report →
Price Chart
About the company
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis.
- CEO
- Cuong Viet Do
- IPO
- 2020
- Employees
- 13
- HQ
- Carson City, NV, US
Get TickerSpark's AI analysis on BIVI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.58M
- P/E
- -0.31
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.15
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -174.88%
- ROIC
- -339.33%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-22,651,733
- Net Income
- $-22,072,863-25.8%
- EPS
- $-3.05+74.8%
- OCF Growth
- -99897.9%
- FCF Growth
- -99897.9%
- 52W High
- $3.79
- 52W Low
- $0.75
- 50D MA
- $1.38
- 200D MA
- $1.52
- Beta
- 0.78
- RSI (14)
- 31
- Avg Volume
- 568.61K
No earnings-call transcripts are available for BIVI yet.
- Free Float
- 96.4%
- Shares Outstanding
- 10.72M
- Float Shares
- 10.34M
of shares held by institutions
38 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 1.05M | ▲ 443.25K |
| Jane Street Group, LLC | 230.66K | ▲ 194.80K |
| Vanguard Group Inc | 213.53K | ▲ 84.60K |
| Citadel Advisors LLC | 95.95K | ▲ 50.66K |
| Acadian Asset Management LLC | 80.83K | ▲ 80.83K |
| Geode Capital Management, LLC | 75.77K | ▲ 5.02K |
| State Street Corp | 73.10K | ▲ 73.10K |
| Vanguard Capital Management LLC | 70.91K | 0 |
| Philadelphia Trust Co | 50.01K | 0 |
| Vanguard Fiduciary Trust Co | 37.56K | 0 |
| Northern Trust Corp | 21.82K | 0 |
| Gsa Capital Partners Llp | 21.13K | ▲ 21.13K |
Held by 7 ETFs
Biggest fund positions in BIVI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | DO CUONG V | buy | 2,500 |
| Nov 13, 26 | DO CUONG V | buy | 2,500 |
| Aug 28, 26 | Palumbo Joseph M | buy | 4,843 |
| Aug 28, 26 | Chappell Amy Suzon | buy | 727 |
| Aug 28, 26 | KIM JOANNE WENDY | buy | 2,500 |
| Aug 27, 26 | DO CUONG V | buy | 15,210 |
| Jan 5, 26 | Palumbo Joseph M | other | 132,000 |
| Jan 5, 26 | KIM JOANNE WENDY | other | 110,100 |
| Jan 5, 26 | ROGICH SIGMUND | other | 141,100 |
| Jan 5, 26 | ROGICH SIGMUND | other | 70,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIVI coverage
Recent articles, reports, and earnings notes.
No research on BIVI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIVI report →BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026
globenewswire.com · Nov 16
BioVie Invited to Present Data on Bezisterim in Parkinson's Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson's Diseases
globenewswire.com · Nov 10
BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
globenewswire.com · Nov 9
BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
globenewswire.com · Nov 4
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
globenewswire.com · Nov 2
BioVie Inc. (NASDAQ:BIVI) Shares Shorted: Short Interest Down 34.5% in October
defenseworld.net · Nov 2
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH's RECOVER-TLC Third Annual Workshop
globenewswire.com · Oct 26
BioVie reports positive Phase 2 Parkinson's data for bezisterim
proactiveinvestors.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.